Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Cancer: Correlation with Grade Groups (WHO 2016) and ERG and PTEN Status

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2019 Jun 19

PMID 31209634

Citations 10

Authors

Raquel Albero-Gonzalez

Silvia Hernandez-Llodra

Nuria Juanpere

Marta Lorenzo

Adria Lloret

Laura Segales

Xavier Duran

Lluis Fumado

Lluis Cecchini

Josep Lloreta-Trull

Affiliations

Soon will be listed here.

Abstract

The role of DNA MMR genes in prostate cancer (PrCa) is controversial, as genetic alterations leading to microsatellite instability are incompletely defined in these tumors. ERG rearrangements and PTEN loss are concomitant events in PrCa. The aim of this study has been to analyze the immunohistochemical (IHC) expression of MSH2, MSH6, MLH1, PMS2, ERG, and PTEN and their potential association with the grade group (GG) grading system (WHO 2016) and PSA recurrence in a series of 200 PrCa (PSMAR-Biobank, Barcelona, Spain). MSH2, MLH1, PMS2, and PTEN losses were documented in 8%, 5%, 2%, and 36.5%, respectively. ERG expression was found in 48%. MSH6 showed an increase of expression with respect to basal levels in 42.1% of the cases. A statistical association between MSH6 overexpression and GG5 was found (p = 0.0281). ERG-wild-type cases were associated with single MSH2 loss (p = 0.024), and MSH2 and/or MLH1 loss (p = 0.019). The percentage of cases with PTEN loss was 20.5% (8/39) in GG1, 37.6% (53/141) of clustered GG2 to 4, and 60% (12/20) of GG5 (chi-square test, p = 0.01). Thus, PTEN expression loss was statistically more frequent in the upper-grade tumors. PMS2 loss was an infrequent event, but it was statistically associated with shorter time to PSA recurrence (p = 0.011). These results suggest the existence of an alternative non-ERG pathway associated with MSH2 or MLH1 expression loss. MSH6 overexpression could be a marker of aggressiveness in PrCa. The IHC assessment of DNA MMR proteins, ERG and PTEN, could identify different altered PrCa pathways, which could aid patient stratification.

Citing Articles

MRE11A: a novel negative regulator of human DNA mismatch repair.

Du D, Yang Y, Zhang Y, Wang G, Chen L, Guan X Cell Mol Biol Lett. 2024; 29(1):37.

PMID: 38486171 PMC: 10938699. DOI: 10.1186/s11658-024-00547-z.

Clinicopathological and molecular analysis of microsatellite instability in prostate cancer: a multi-institutional study in China.

Zhang H, Yang X, Xie J, Cheng X, Chen J, Shen M Front Oncol. 2023; 13:1277233.

PMID: 37901334 PMC: 10613026. DOI: 10.3389/fonc.2023.1277233.

Recent Research Advances in Double-Strand Break and Mismatch Repair Defects in Prostate Cancer and Potential Clinical Applications.

Jaworski D, Brzoszczyk B, Szylberg L Cells. 2023; 12(10).

PMID: 37408208 PMC: 10216954. DOI: 10.3390/cells12101375.

Uncovering the Secrets of Prostate Cancer's Radiotherapy Resistance: Advances in Mechanism Research.

Lyu F, Shang S, Gao X, Ma M, Xie M, Ren X Biomedicines. 2023; 11(6).

PMID: 37371723 PMC: 10296152. DOI: 10.3390/biomedicines11061628.

Correlations of PTEN and ERG Immunoexpression in Prostate Carcinoma and Lesions Related to Its Natural History: Clinical Perspectives.

Voulgari O, Goutas D, Pergaris A, Belogiannis K, Thymara E, Kavantzas N Curr Issues Mol Biol. 2023; 45(4):2767-2780.

PMID: 37185705 PMC: 10136580. DOI: 10.3390/cimb45040181.

References

Kolodner R, Marsischky G . Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999; 9(1):89-96. DOI: 10.1016/s0959-437x(99)80013-6. View

Wood R, Mitchell M, Sgouros J, Lindahl T . Human DNA repair genes. Science. 2001; 291(5507):1284-9. DOI: 10.1126/science.1056154. View

Chen Y, Wang J, Fraig M, Metcalf J, Turner W, Bissada N . Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 2001; 61(10):4112-21. View

Velasco A, Hewitt S, Albert P, Hossein M, Rosenberg H, Martinez C . Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer. 2002; 94(3):690-9. DOI: 10.1002/cncr.10247. View

Velasco A, Albert P, Rosenberg H, Martinez C, Leach F . Clinicopathologic implications of hMSH2 gene expression and microsatellite instability in prostate cancer. Cancer Biol Ther. 2002; 1(4):362-7. View

Srivastava T, Chattopadhyay P, Mahapatra A, Sarkar C, Sinha S . Increased hMSH2 protein expression in glioblastoma multiforme. J Neurooncol. 2004; 66(1-2):51-7. DOI: 10.1023/b:neon.0000013482.99032.b0. View

Shia J, Klimstra D, Nafa K, Offit K, Guillem J, Markowitz A . Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol. 2004; 29(1):96-104. DOI: 10.1097/01.pas.0000146009.85309.3b. View

Tomlins S, Rhodes D, Perner S, Dhanasekaran S, Mehra R, Sun X . Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310(5748):644-8. DOI: 10.1126/science.1117679. View

Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Obermann E, Wieland W . Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J Mol Med (Berl). 2006; 84(10):833-41. DOI: 10.1007/s00109-006-0074-0. View

10.

Norris A, Woodruff R, DAgostino Jr R, Clodfelter J, Scarpinato K . Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate. 2006; 67(2):214-25. DOI: 10.1002/pros.20522. View

11.

Li G . Mechanisms and functions of DNA mismatch repair. Cell Res. 2007; 18(1):85-98. DOI: 10.1038/cr.2007.115. View

12.

Li M, Liu L, Wang Z, Wang L, Liu Z, Xu G . Overexpression of hMSH2 and hMLH1 protein in certain gastric cancers and their surrounding mucosae. Oncol Rep. 2008; 19(2):401-6. View

13.

Norris A, Gentry M, Peehl D, DAgostino Jr R, Scarpinato K . The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2009; 18(1):57-64. PMC: 2701238. DOI: 10.1158/1055-9965.EPI-08-0377. View

14.

King J, Xu J, Wongvipat J, Hieronymus H, Carver B, Leung D . Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009; 41(5):524-6. PMC: 2898503. DOI: 10.1038/ng.371. View

15.

Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A . Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41(5):619-24. PMC: 2835150. DOI: 10.1038/ng.370. View

16.

Han B, Mehra R, Lonigro R, Wang L, Suleman K, Menon A . Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009; 22(8):1083-93. PMC: 2760294. DOI: 10.1038/modpathol.2009.69. View

17.

Tomlins S, Bjartell A, Chinnaiyan A, Jenster G, Nam R, Rubin M . ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009; 56(2):275-86. DOI: 10.1016/j.eururo.2009.04.036. View

18.

Clark J, Cooper C . ETS gene fusions in prostate cancer. Nat Rev Urol. 2009; 6(8):429-39. DOI: 10.1038/nrurol.2009.127. View

19.

Langeberg W, Kwon E, Koopmeiners J, Ostrander E, Stanford J . Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Cancer Epidemiol Biomarkers Prev. 2010; 19(1):258-64. PMC: 2825566. DOI: 10.1158/1055-9965.EPI-09-0800. View

20.

Esgueva R, Perner S, LaFargue C, Scheble V, Stephan C, Lein M . Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol. 2010; 23(4):539-46. PMC: 2848699. DOI: 10.1038/modpathol.2009.193. View